ChinaAMC SSE STAR Biology and Medicine ETF(588130.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
ChinaAMC SSE STAR Biology and Medicine ETF
588130.SH
News
View More

CSPC Pharmaceutical Grants Shares to Employees Under Award Scheme

CSPC Pharmaceutical Group Ltd. has announced the grant of awarded shares under its share award scheme, which has been in place since 2018. The latest grant continues the practice of satisfying share awards through on-market purchases by a trustee, using existing shares rather than issuing new ones. Awarded shares will be vested to selected individuals funded by shares already held by the trustee.

Reuters·
SH
512290
+0.87%
SH
562050
+0.10%
SH
512010
-0.26%
Reuters·
SH
512290
+0.87%
SH
562050
+0.10%
SH
512010
-0.26%

02:00 ET HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline

HanchorBio, Inc. has entered a strategic partnership with WuXi Biologics to advance its next-generation bi- and multi-functional fusion protein pipeline. The collaboration will leverage WuXi's end-to-end biologics development and manufacturing services to enhance clinical translation and manufacturing efficiency. This partnership aims to accelerate the development of HanchorBio's innovative fusion proteins, supporting its proprietary Fc-Based Designer Biologics (FBDB™) platform. Both companies emphasize the importance of execution speed and scalability in bringing transformative therapies to patients worldwide.

prnewswire·
SH
516500
+1.21%
SH
516930
+1.51%
SZ
159837
+0.77%
prnewswire·
SH
516500
+1.21%
SH
516930
+1.51%
SZ
159837
+0.77%

Jiangzhong Pharmaceutical Affiliate Posts 16.6% Operating Profit Growth for 2025

China Resources Jiangzhong Pharmaceutical Co., Ltd. reported a 16.6% growth in operating profit for 2025, with total operating revenue of RMB 4.2195 billion and an operating profit of RMB 1.1985 billion. The net profit attributable to shareholders was RMB 906.12 million. Jiangzhong Pharmaceutical is a subsidiary of China Resources Pharmaceutical Group Ltd., which holds a 26.12% interest in the company. The financial information is based on unaudited preliminary results for the year ended December 31, 2025.

Reuters·
SH
512290
+0.87%
SH
588130
-1.05%
SH
589720
-0.97%
Reuters·
SH
512290
+0.87%
SH
588130
-1.05%
SH
589720
-0.97%

CSPC PHARMA granted over 46.46 million shares as rewards

CSPC PHARMA granted 46.4625 million restricted shares to 727 employees under the share award plan, accounting for approximately 0.4% of the total issued shares. Based on the closing price of 9.81 yuan, the amount involved is approximately 456 million yuan. The awarded shares will vest in three batches, with the number granted depending on the respective performance targets, with a deadline of December 31, 2028

AASTOCKS·
SH
512290
+0.87%
SH
510660
-0.44%
SH
512010
-0.26%
AASTOCKS·
SH
512290
+0.87%
SH
510660
-0.44%
SH
512010
-0.26%

TYK MEDICINES has obtained a drug production license from the Zhejiang Provincial Drug Administration

TYK MEDICINES-B announced that it has received a drug manufacturing license issued by the Zhejiang Provincial Drug Administration, allowing the production of Alectinib Mesylate Tablets. This is expected to have a long-term positive impact on the company's capacity expansion and market development, laying the foundation for subsequent commercial production

AASTOCKS·
HK
02410
-2.16%
SH
516500
+1.21%
SH
510660
-0.44%
AASTOCKS·
HK
02410
-2.16%
SH
516500
+1.21%
SH
510660
-0.44%
© 2026 Longbridge｜Disclaimer